Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of FOLFOX6 + bevacizumab in initially unresectable colorectal liver metastases
2005-002269-35Phase 2Terminated
- Sponsor
- AOU Policlinico di Modena
- Start
- Aug 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in colon cancer, rectal cancer and colorectal cancer (CRC), sponsored by AOU Policlinico di Modena. Primary endpoint: Rate of complete liver metastasis resection. Started Aug 2007; status: terminated.
02
Drugs
bevacizumab
03
Conditions
colon cancerrectal cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on 2005-002269-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002269-35.